On Friday, January 26, Penn Medicine’s Abramson Cancer Center and the Leukemia & Lymphoma Society will offer
2018 Updates in Hematologic Malignancies with Proceedings from International Medical Meetings.
This daylong CME course has been specifically designed for health care professionals treating blood cancer patients, including hematologists, medical and radiation oncologists, primary care physicians and nurses.
Course attendees will acquire up-to-date, practical information with immediate clinical application, including the ability to
- discuss the clinical features and differential diagnoses for various hematologic malignancies;
- define genomic analyses for hematologic malignancies;
- apply new strategies for incorporating therapies that target metabolism in blood cancers; and
- summarize patient management issues associated with hematologic malignancies.
“This course offers a comprehensive review of research developments in hematologic malignancies from 2017 for any health care professional with an interest in blood cancers,” Activity Director Edward A. Stadtmauer, MD explains. Dr. Stadtmauer is Chief of the Hematologic Malignancies Section in the Division of Hematology Oncology and Co-Leader of the Hematologic Malignancies Research Program at the Abramson Cancer Center.
Speakers include Co-Directors Edward A. Stadtmauer, MD, Selina M. Luger, MD and Stephen J. Schuster, MD, who each lead subspecialty divisions at Abramson Cancer Center; and over a dozen additional Penn faculty members who will give didactic presentations and lead panel discussions.
For questions or additional information, please email Barbara Lopez at Barbara.Lopez@uphs.upenn.edu.
Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education and the American Nurses Credentialing Center.